COMMUNIQUÉS West-GlobeNewswire

Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder

15/02/2018 - 17:06

SAN DIEGO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement for obtaining an exclusive [...]

Sales of Olainfarm in January Exceed 9 Million Euros

15/02/2018 - 17:03

Olaine, 2018-02-15 17:03 CET (GLOBE NEWSWIRE) -- January 2018, consolidated sales Sales, Thsnd. EUR Changes to January 2017 Share in total sales Latvia 2 922 18% 32% Russia 1 716 -27% 19% Belarus 1 696 5% 18% Ukraine 1 [...]

Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

15/02/2018 - 17:00

– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – – Initiation of registrational [...]

Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date

15/02/2018 - 16:30

BATON ROUGE, La., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED ), announced today that it will report results for the fourth quarter and year ended December 31, 2017 after the market closes on February [...]

Sienna Announces February Dividend

15/02/2018 - 16:00

MARKHAM, Ontario, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA ) today announced a dividend of $0.075 per common share of the Company (each, a “Common Share”) for [...]

Solon Eiendom ASA : Notice of extraordinary general meeting

15/02/2018 - 15:13

(Oslo, 15 February 2018) Solon Eiendom ASA (OSE: SOLON), calls for the extraordinary general meeting to be held at the company's offices in Olav Vs gate 5, 0161, Oslo, Norway on 09 March 2018 at 10 am (CET). The notice [...]

Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full

15/02/2018 - 15:00

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, N.S., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Corporation”) (TSX: IMV ) (OTCQX:IMMVF), a [...]

Immunovaccine annonce la clôture d’un placement par voie de prise ferme de 14,375 millions de dollars compte tenu de l’option de surallocation intégralement exercée

15/02/2018 - 15:00

NE PAS DISTRIBUER À DES AGENCES DE TRANSMISSION DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNIS HALIFAX, N.S., 15 févr. 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (« Immunovaccine » ou la « société ») (TSX: IMV ) (OTCQX: [...]

Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance

15/02/2018 - 14:38

NEW HAVEN, Conn., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO ) announced today its launch of the first lung cancer treatment resistance panel specifically for the critical mutations T790M and C797S [...]

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

15/02/2018 - 14:30

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ: ARGS ), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis [...]

Scythian Biosciences Announces Appointment of Professor Michael Barnes as Chief Medical Officer

15/02/2018 - 14:20

- Influential voice in medical cannabis policy in Europe - A leading world authority in neurological rehabilitation TORONTO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the “ Company ” or “ Scythian [...]

CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE® for Pediatric Hereditary Angioedema Use

15/02/2018 - 14:12

**CORRECTION - Shire Announces FDA Acceptance of sBLA for CINRYZE ® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use FDA assigns an action date of June 20, 2018 If approved, CINRYZE will be the [...]

Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference

15/02/2018 - 14:00

YARDLEY, Pa., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN ), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive [...]

Epilepsy Foundation Pipeline Conference to Feature Winners of the SUDEP Challenge on Identifying Biomarkers Predicting Sudden Unexpected Death in Epilepsy (SUDEP)

15/02/2018 - 14:00

LANDOVER, Md., Feb. 15, 2018 (GLOBE NEWSWIRE) -- The Epilepsy Foundation Pipeline Conference will feature the winners of the SUDEP Institute’s 2 nd milestone of its fourth challenge , “Developing Predictive Biomarkers [...]

UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference

15/02/2018 - 14:00

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results

15/02/2018 - 14:00

- GEN-009 neoantigen vaccine advancing to IND filing - - Balance sheet strengthened with $55m gross proceeds from January equity financing - - Conference call today at 9 am ET - CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE [...]

Extendicare Announces February 2018 Dividend of C$0.04 per Share

15/02/2018 - 14:00

MARKHAM, Ontario, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018

15/02/2018 - 14:00

BOSTON, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]

Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer

15/02/2018 - 14:00

BUFFALO, N.Y., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]